Breaking News

Revance Therapeutics announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications reported the impact of DAXXIFY or DaxibotulinumtoxinA-lanm) for injection on brow position and frontalis muscle activity from a post-hoc analysis of patients in the Phase 2a forehead line study and the SAKURA open-label safety study as well as presenting the efficacy and safety of DAXXIFY analyzed by age and race based on a subgroup analysis of the SAKURA glabellar lines clinical trials. "The newly released publications in the Aesthetic Surgery Journal showcase Revance's commitment to generating novel data that helps healthcare providers more fully understand the clinical performance of DAXXIFY ," said Conor Gallagher, PhD, Vice President of Medical Affairs and Scientific Innovation at Revance. "This data demonstrates that treatment of frown lines with DAXXIFY results in an overall positive change in eyebrow position even with a modest reduction in forehead muscle activity."

Revance Therapeutics at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain. The presentation will include results from Revance's JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of three doses of DAXXIFY compared to placebo for adults with upper limb spasticity after stroke or traumatic brain injury. DAXXIFY was found to be effective and well tolerated for treating adult ULS in the Phase 2 JUNIPER study. The duration of response observed in JUNIPER suggests that DAXXIFY has the potential to reduce the frequency of adult ULS treatments by up to 50% annually. "As an investigator in the JUNIPER trial, I am delighted to present data from JUNIPER for the first time at this year's MDS Congress," said Atul Patel, MD, and Medical Director, Kansas Institute of Research. "The data indicates that duration for DaxibotulinumtoxinA for Injection is strong and has the potential to reduce the frequency of adult upper limb spasticity treatments, delivering improvement in patients' quality of life and the opportunity to expand treatment care. With current treatments, 60% of patients report spasticity symptoms return less than 3 months after treatment. 1 The need for a new treatment option is considerable as patients have overwhelmingly indicated the desire for a longer lasting option."